| pubmed-article:7904244 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7904244 | lifeskim:mentions | umls-concept:C0082341 | lld:lifeskim |
| pubmed-article:7904244 | lifeskim:mentions | umls-concept:C0206128 | lld:lifeskim |
| pubmed-article:7904244 | lifeskim:mentions | umls-concept:C0332120 | lld:lifeskim |
| pubmed-article:7904244 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7904244 | pubmed:dateCreated | 1994-2-14 | lld:pubmed |
| pubmed-article:7904244 | pubmed:abstractText | The activation constants (KA; dose required to occupy 50% of receptors) for reversal of gamma-butyrolactone (GBL)-induced elevation of striatal L-3,4-dihydroxyphenylalanine (L-DOPA) levels via stimulation of presynaptic dopamine receptors were determined for apomorphine and two dopamine D3 receptor-selective agonists, quinpirole and LY163502 (quinelorane). The KA values correlated significantly with the affinities (Ki) of the agonists for the D3 (r = 0.999, P < 0.05) but not the D2 (r = -0.13) receptor, suggesting that striatal synthesis-inhibiting autoreceptors are of the D3 rather than the D2 subtype. | lld:pubmed |
| pubmed-article:7904244 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7904244 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7904244 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7904244 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:7904244 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:7904244 | pubmed:author | pubmed-author:GoldsteinMM | lld:pubmed |
| pubmed-article:7904244 | pubmed:author | pubmed-author:MellerEE | lld:pubmed |
| pubmed-article:7904244 | pubmed:author | pubmed-author:BohmakerKK | lld:pubmed |
| pubmed-article:7904244 | pubmed:author | pubmed-author:BashamD ADA | lld:pubmed |
| pubmed-article:7904244 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7904244 | pubmed:day | 2 | lld:pubmed |
| pubmed-article:7904244 | pubmed:volume | 249 | lld:pubmed |
| pubmed-article:7904244 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7904244 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7904244 | pubmed:pagination | R5-6 | lld:pubmed |
| pubmed-article:7904244 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:meshHeading | pubmed-meshheading:7904244-... | lld:pubmed |
| pubmed-article:7904244 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:7904244 | pubmed:articleTitle | Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors. | lld:pubmed |
| pubmed-article:7904244 | pubmed:affiliation | Millhauser Laboratories, New York University School of Medicine, NY 10016. | lld:pubmed |
| pubmed-article:7904244 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7904244 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7904244 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7904244 | lld:pubmed |
